ALBANY, Ore., Dec. 18 /PRNewswire-FirstCall/ -- To validate its on-going efforts to be a responsible environmental steward, Synthetech, Inc. today announced that it has achieved ISO 14001:2004 certification as verified by Underwriters Laboratories, Inc.
The ISO 14001 Standard is an internationally accepted standard for environmental management systems created by the International Organization for Standardization to help organizations minimize how their operations affect the environment, comply with related laws, regulations, and requirements, and establish continuous improvement practices.
“Synthetech is dedicated to accountable environmental practices and our employees are committed to responsible planning to ensure we safeguard the environment,” said Dr. Greg Hahn, President and COO. “With a core environmental, health, safety, and security-focused culture, we have now formalized our systems to utilize the ISO14001 standards and it’s concept of plan, do, check, and act to continuously improve our environmental performance and have the least impact on our environment and burden for future generations.”
As part of the efforts to achieve this well-recognized certification, Synthetech has established its own Environmental Management System (EMS) to ensure that their activities, products, and services have minimal impact on or risk to the environment. Synthetech’s EMS helps monitor and improve upon environmental areas within their operations, such as toxic chemical and hazardous waste reduction, resource conservation, employee and community involvement, and long term environmental capital improvement opportunities.
“The Synthetech Team has been instrumental in ensuring that our Environmental Management System is effectively implemented including identifying ways to reduce, reuse, and recycle waste and minimize energy usage,” said Deron Neukomm, Quality Assurance/Environmental, Health, Safety, and Security Manager.
Synthetech, Inc. is a fine chemicals company specializing in organic synthesis, biocatalysis and chiral technologies. Synthetech develops and manufactures amino acid derivatives, specialty amino acids, peptide fragments, proprietary custom chiral intermediates and specialty resins, primarily for the pharmaceutical industry. Synthetech’s products support the development and manufacture of therapeutic peptides and peptidomimetic small molecule drugs at every stage of a customer’s clinical development pipeline, and are used in drugs for the treatment of AIDS, cancer, cardiovascular and other diseases.
http://www.synthetech.cominvestor@synthetech.com
CONTACT: Deron Neukomm of Synthetech, Inc., +1-541-967-6575,
investor@synthetech.com
Web site: http://www.synthetech.com/
